Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions.

[1]  David C. Atkins,et al.  A quantitative reverse transcriptase-polymerase chain reaction assay to identify metastatic carcinoma tissue of origin. , 2006, The Journal of molecular diagnostics : JMD.

[2]  K. Hess,et al.  Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP) , 2005 .

[3]  N. Pavlidis,et al.  Cancer of unknown primary (CUP). , 2005, Critical reviews in oncology/hematology.

[4]  Adam Kowalczyk,et al.  An expression-based site of origin diagnostic method designed for clinical application to cancer of unknown origin. , 2005, Cancer research.

[5]  J. Komorowski,et al.  Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm , 2005, Clinical Cancer Research.

[6]  Daniel J Sargent,et al.  New treatment options for colorectal cancer. , 2004, The New England journal of medicine.

[7]  Tsung-Teh Wu,et al.  Reduced Expression of Cytokeratin 20 in Colorectal Carcinomas With High Levels of Microsatellite Instability , 2004, The American journal of surgical pathology.

[8]  S. Culine,et al.  Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002) , 2003, British Journal of Cancer.

[9]  M. Loda,et al.  CDX-2 Homeobox Gene Expression Is a Reliable Marker of Colorectal Adenocarcinoma Metastases to the Lungs , 2003, The American journal of surgical pathology.

[10]  L. Sobin,et al.  Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract , 2003, Histopathology.

[11]  E. Wit,et al.  Identification from public data of molecular markers of adenocarcinoma characteristic of the site of origin. , 2002, Cancer research.

[12]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Welsh,et al.  Molecular classification of human carcinomas by use of gene expression signatures. , 2001, Cancer research.

[14]  P. Chu,et al.  Cytokeratin 7 and Cytokeratin 20 Expression in Epithelial Neoplasms: A Survey of 435 Cases , 2000, Modern Pathology.

[15]  J. Hainsworth,et al.  Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  W. Blumenfeld,et al.  Utility of cytokeratin 7 and 20 subset analysis as an aid in the identification of primary site of origin of malignancy in cytologic specimens , 1999, Diagnostic cytopathology.

[17]  R. Moll,et al.  Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. , 1992, The American journal of pathology.

[18]  T. Tot.  Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. , 2002, European journal of cancer.